Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis

Molecular Cancer Research

Volumn 7, Issue 10, 2009, Pages 1613-1621

  Ma, Wei Feng ^a   Du, Jun ^b   Fu, Liu Peng ^c   Fang, Rui ^b   Chen, Hong Yuan ^d   Cai, Shao Hui ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHIMERIC PROTEIN; PROTEIN TAT/54R/KDEL; RECOMBINANT PROTEIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; KNOCKOUT GENE; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL MIGRATION INHIBITION; CHEMOKINE CXCL12; ENDOPLASMIC RETICULUM; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; PHENOTYPE; PROTEIN BINDING; RECEPTORS, CXCR4; RECOMBINANT FUSION PROTEINS;

EID: 72449187631     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0078     Document Type: Article

References (35)

1. Arya M, Patel HR, McGurk C, et al. The importance of the CXCL12-4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 2004;4:291-303. (Pubitemid 40189442)
2. Darash-Yahana M, PikarskyE, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-1242 (Pubitemid 39561563)
3. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005;65:967-971 (Pubitemid 40216458)
4. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56 (Pubitemid 32225831)
5. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001;61:4961-4965
6. Cai SH, Tan Y, Ren XD, Li XH, Cai SX, Du J. Loss of C-terminal α-helix decreased CXCL12α-mediated signaling and chemotaxis without influencing CXCR4 internalization. Acta Pharmacol Sin 2004;25:152-160 (Pubitemid 38186163)
7. Wheeler YY, Chen SY, Sane DC. Intrabody and intrakine strategies for molecular therapy. Mol Ther 2003;8:355-366
8. Bai X, Chen JD, Yang AG, Torti F, Chen SY. Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Gene Ther 1998;5:984-994 (Pubitemid 28371916)
9. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003; 63:3833-3839 (Pubitemid 36793074)
10. Schwarze SR, Dowdy SF . In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000;21:45-48
11. Watson K, Edwards RJ. HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. Biochem Pharmacol 1999;58:1521-1528 (Pubitemid 29467336)
12. Wadia JS, Dowdy SF . Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005;57:579-596 (Pubitemid 40255562)
13. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998;4:1449-1452 (Pubitemid 28553472)
14. Becker-Hapak M, McAllister SS, DowdySF . TAT-mediated protein transduction into mammalian cells. Methods 2001;24:247-256
15. Jin LH, Bahn JH, Eum WS, et al. Transduction of human catalase mediated byan HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. Free Radic Biol Med 2001;31:1509-1519
16. Nilsson T, Jackson M, Peterson PA. Short cytoplasmic sequences serve as retention signals for transmembrane proteins in the endoplasmic reticulum. Cell 1989;58:707-718 (Pubitemid 19210964)
17. Jackson MR, Nilsson T, Peterson PA. Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum. EMBO J 1990;9:3153-3162 (Pubitemid 20282527)
18. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987;48:899-907.
19. Pelham HR. Evidence that luminal ER proteins are sorted from secreted proteins in a post-ER compartment. EMBO J 1988;7:913-918
20. Kwon HY, Eum WS, Jang HW, et al. Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells. FEBS Lett 2000;485:163-167
21. Han JM, Park SG, Liu B, et al. Aminoacyl-tRNA synthetase-interacting multifunctional protein 1/p43 controls endoplasmic reticulum retention of heat shock protein gp96: its pathological implications in lupus-like autoimmune diseases. Am J Pathol 2007;170:2042-2054 (Pubitemid 47339277)
22. Sato T, Sato M, Kiyohara K, et al. Molecular cloning and characterization of a novel human β1,3-glucosyltransferase, which is localized at the endoplasmic reticulum and glucosylates O-linked fucosylglycan on thrombospondin type 1 repeat domain. Glycobiology 2006;16:1194-1206 (Pubitemid 44811583)
23. Le-Niculescu H, Niesman I, Fischer T, DeVries L, Farquhar MG. Identification and characterization of GIV, a novel Gα i/s-interacting protein found on COPI, endoplasmic reticulum-Golgi transport vesicles. J Biol Chem 2005;280: 22012-22020 (Pubitemid 40827855)
24. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (CXCL12). J Exp Med 1996;184:1101-1109
25. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the CXCL12-4 axis. Stem Cells 2005;23:879-894 (Pubitemid 41170944)
26. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-8612 (Pubitemid 39552073)
27. Lo AS, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 2008:343-373
28. Snyder EL, Saenz CC, Denicourt C, et al. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res 2005;65:10646-10650 (Pubitemid 41713328)
29. Studebaker AW, Ariza ME, Williams MV. Depletion of uracil-DNA glycosylase activity is associated with decreased cell proliferation. Biochem Biophys Res Commun 2005;334:509-515
30. Gondeau C, Gerbal-Chaloin S, Bello P, Aldrian-Herrada G, Morris MC, Divita G. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J Biol Chem 2005;280:13793-13800 (Pubitemid 40517276)
31. Asoh S, Ohsawa I, Mori T, et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci U S A 2002;99:17107-17112 (Pubitemid 36034106)
32. Cao G, Pei W, Ge H, et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injuryand neuronal apoptosis. J Neurosci 2002;22:5423-5431
33. Dietz GP, Kilic E, Bahr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol Cell Neurosci 2002;21: 29-37. (Pubitemid 35178497)
34. Horuk R. Chemokines beyond inflammation. Nature 1998;393:524-525
35. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines, physiologic and clinical implications. Cancer 1994;73: 2432-2443 (Pubitemid 24129130)